|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Veritas Pharma Inc. (CSE:VRT) (VRTHF) (2VP.F), (“Veritas” or the “Company”) is pleased to announce that it has entered into a Memorandum of Understanding (“MOU”) with Colombian medical cannabis company Foliumed S.A.S. (“Foliumed”). Under the terms of the MOU, Veritas and Foliumed will jointly conduct scientific research, undertake product development activities, and commercialize select medical cannabis products with the help of Veritas’ research arm, Cannevert Therapeutics Ltd. (“CTL”).
Veritas Pharma Inc. (CSE:VRT) (VRTHF) (2VP.F), (“Veritas” or the “Company”) is pleased to provide a corporate update on its achievements, related scientific activities and growth strategies for the second quarter of fiscal 2018. Earlier this year, Veritas Pharma’s subsidiary Cannevert Therapeutics (“CTL”) signed an agreement with Puerto Rico’s Fundación de Investigación (“FDI”) Clinical Research to perform trials of its lead cannabis strain, CTL-X, to target pain.
Veritas Pharma Inc. (CSE:VRT) (VRTHF) (2VP.F), (“Veritas” or the “Company”) is pleased to announce with the dealer licence being granted which was previously announced on December 28, 2017, the Company has now engaged a branding firm in the development of label and package design in compliance of Health Canada regulations. Veritas is applying to amend Cannevert’s Dealer Licence such that the Company can package Cannevert products including CTL-X for sale to licensed producers in Canada and for the export market. CBD Strategy Group, a cannabis brand and marketing firm, has been retained to help develop brand strategy and guidelines around compliant packaging and labeling for both cannabis import and export.
Veritas Pharma Inc. (CSE:VRT) (VRTHF) (2VP.F), (“Veritas” or the “Company”) provides the following statement to the recommendation issued by Members of the Standing Senate Committee on Aboriginal Peoples calling for a one-year deferment to allow for further consultation with Indigenous groups on May 1, 2018. Members of the of the Standing Senate Committee on Aboriginal Peoples in the Canadian Senate are recommending the Liberal government hold back on legalizing cannabis for up to a year in order to address its potential for harmful effects in Indigenous communities. The committee, chaired by Liberal Saskatchewan Sen. Lillian Dyck, said in its report on Bill C-45 that the government simply did not consult enough with First Nations, Inuit and Métis communities before pushing ahead with its plan to legalize the drug.
VANCOUVER, British Columbia, May 07, 2018-- Veritas Pharma Inc., is pleased to announce the establishment of new subsidiary Veritas Pharma Puerto Rico LLC in the US territory. With the management and regulatory ...
In this article, I’m going to take a look at Veritas Pharma Inc’s (DB:2VP) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...
VANCOUVER, British Columbia, April 18, 2018-- Veritas Pharma Inc., is pleased to announce that Dr. Michael K. Pugsley PhD, FBPhS, DSP, a consultant in safety pharmacology, has joined its advisory board. ...
3 Carbon is in the business of designing cannabis extraction facilities and utilizing its own proprietary extraction methods. VANCOUVER, British Columbia, April 16, 2018-- Veritas Pharma Inc. is pleased ...
VANCOUVER, British Columbia, March 29, 2018-- Veritas Pharma Inc. is pleased to announces the closing of a private placement of units. Under the terms of the Private Placement Offering, the Company will ...
VANCOUVER, British Columbia, March 21, 2018-- Veritas Pharma Inc. is pleased to announce the Company has completed the 100% takeover of its research arm, Cannevert Therapeutics Ltd... As previously announced ...
CALGARY, Feb. 28, 2018 /CNW/ - BioCan Technologies Inc. ("BioCan" or the "Company") is pleased to announce that it has entered into a Memorandum of Understanding ("MoU") with Veritas Pharma Inc. ("Veritas") (CSE:VRT) (VRTHF) (Frankfurt: 2VP) to collaborate with Veritas on an exclusive basis to undertake further investigations of cannabis strains being developed by the research arm of Veritas, Cannevert Therapeutics Ltd. ("CTL"). The focus will be to optimize the genetics of their cannabis plants for scientific and clinical testing over the next two years. Pursuant to the MoU, definitive agreements in respect of the transactions contemplated in the MoU are expected to be executed by the parties on or before July 31, 2018. BioCan's CEO, Trevor Peters, stated "We are pleased to be working with Veritas and their scientific teams to develop medically relevant cannabis strains and cannabinoid formulations with optimal therapeutic properties.